Rockwell Medical Inc. (RMTI) Shares Down 1.7%
Rockwell Medical Inc. (NASDAQ:RMTI) shares were down 1.7% during mid-day trading on Thursday . The stock traded as low as $7.03 and last traded at $7.04, with a volume of 243,476 shares changing hands. The stock had previously closed at $7.16.
Several research analysts recently issued reports on RMTI shares. Zacks Investment Research raised Rockwell Medical from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 5th. BTIG Research started coverage on Rockwell Medical in a research report on Friday, August 19th. They set a “buy” rating and a $12.00 target price on the stock. Three analysts have rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company’s stock. Rockwell Medical has a consensus rating of “Hold” and a consensus price target of $11.00.
The company has a 50 day moving average price of $7.63 and a 200 day moving average price of $7.86. The firm’s market cap is $367.90 million.
Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Monday, August 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. During the same period in the prior year, the company earned ($0.05) earnings per share. The firm earned $12.50 million during the quarter, compared to analysts’ expectations of $13.86 million. The business’s quarterly revenue was down 3.5% on a year-over-year basis. Equities research analysts anticipate that Rockwell Medical Inc. will post ($0.36) EPS for the current fiscal year.
In other news, Director Kenneth L. Holt sold 3,692 shares of the stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $7.31, for a total value of $26,988.52. Following the completion of the transaction, the director now owns 63,475 shares of the company’s stock, valued at approximately $464,002.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kenneth L. Holt sold 9,520 shares of the stock in a transaction that occurred on Thursday, August 25th. The stock was sold at an average price of $6.37, for a total value of $60,642.40. Following the completion of the transaction, the director now directly owns 56,048 shares of the company’s stock, valued at approximately $357,025.76. The disclosure for this sale can be found here.
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.